Update: Siponimod (Mayzent) for Secondary Progressive MS
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the Neurological Advisory Committee regarding appropriate Special Authority criteria. PTAC’s recommendation noted specifically the consideration of […]
Calling all people with Secondary Progressive MS
Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC in August. Siponimod has been shown to have benefits for those with Secondary Progressive MS. […]